Clinical Trial Update: A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating trastuzumab deruxtecan in combination with immunotherapy as neoadjuvant treatment for HR-positive, HER2-low early-stage breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Low Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Guangzhou Women and Children's Medical Center | Conditions: Breast Cancer, Estrogen Receptor-Positive, HER2 Low Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING